Anti-HIV Immune Serum Globulin (Human)

DRUG4 trials

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Allergy and Infectious Diseases (NIAID), Abbott

Conditions

HIV InfectionsPregnancy

Phase 1

A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children

CompletedNCT00000827

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 1998-04-30Target: 45Updated: 2021-11-04

Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

CompletedNCT00002036

AbbottHIV Infections

Target: 12Updated: 2009-02-20

Phase 2

The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants

TerminatedNCT00000961

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 112Updated: 2021-11-04

Phase 3

A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)

CompletedNCT00000751

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)HIV Infections, Pregnancy

End: 2007-08-31Target: 1600Updated: 2008-09-30